O
ALXO icon

OrbiMed’s ALX Oncology ALXO Stock Holding History

OrbiMed’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.75M Buy
+2,866,256
New +$5.46M 0.11% 91
2024
Q3 		– Sell
-1,894,462
Closed -$11.4M – 119
2024
Q2 		$11.4M Sell
1,894,462
-823,508
-30% -$10.1M 0.23% 71
2024
Q1 		$30.3M Sell
2,717,970
-377,030
-12% -$5.3M 0.56% 50
2023
Q4 		$46.1M Buy
3,095,000
+224,000
+8% +$2.13M 0.92% 41
2023
Q3 		$13.8M Hold
2,871,000
– – 0.29% 72
2023
Q2 		$21.6M Hold
2,871,000
– – 0.39% 68
2023
Q1 		$13M Hold
2,871,000
– – 0.25% 80
2022
Q4 		$32.4M Hold
2,871,000
– – 0.62% 54
2022
Q3 		$27.5K Buy
2,871,000
+684,731
+31% +$7.98M 0.51% 61
2022
Q2 		$17.7K Buy
2,186,269
+1,564,569
+252% +$17M 0.32% 68
2022
Q1 		$10.5M Buy
621,700
+414,100
+199% +$7.07M 0.17% 99
2021
Q4 		$4.46M Buy
207,600
+57,600
+38% +$2.48M 0.06% 138
2021
Q3 		$11.1M Hold
150,000
– – 0.12% 123
2021
Q2 		$8.2M Hold
150,000
– – 0.08% 134
2021
Q1 		$11.1M Hold
150,000
– – 0.1% 119
2020
Q4 		$12.9M Buy
+150,000
New +$9.02M 0.11% 117

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

OrbiMed's ALXO Position: Q1 2026 in Review

OrbiMed opened a new position in ALX Oncology (ALXO) in Q1 2026: 2,866,256 shares worth $5.75M. The stake represents 0.11% of the portfolio and ranks #91 among its holdings. This is a return to the name: OrbiMed previously reported a position in ALXO as recently as Q2 2024.

OrbiMed first reported a position in ALXO in Q4 2020 and has held it in 16 quarters since. The position peaked at $46.1M in Q4 2023. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • OrbiMed held 2,866,256 shares of ALX Oncology worth $5.75M as of Q1 2026.
  • ALX Oncology was a new OrbiMed position in Q1 2026.
  • ALX Oncology made up 0.11% of OrbiMed's portfolio in Q1 2026, its #91 holding.
  • OrbiMed first reported a position in ALX Oncology in Q4 2020 and has held it in 16 quarters since.
  • OrbiMed's ALX Oncology position peaked at $46.1M in Q4 2023.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.